Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | CTSG | P08311 | 1/20 | 0.56 |
| ▸ | ACLY | P53396 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26136410 | 0.88 | ELANE (0.57) | ELANEEPHX2CTSGACLYMAPT | |
| SCHEMBL16226540 | 0.85 | EPHX2 (0.65) | ELANEEPHX2ACLYMAPTALDH1A1 | |
| SCHEMBL31746123 | 0.85 | EPHX2 (0.63) | ELANEEPHX2ACLYMAPTALDH1A1 | |
| SCHEMBL16226235 | 0.84 | EPHX2 (0.76) | ELANEEPHX2ACLYMAPTALDH1A1 | |
| SCHEMBL23199061 | 0.80 | ELANE (0.78) | ELANEEPHX2CTSGACLYMAPT | |
| SCHEMBL16227224 | 0.80 | EPHX2 (0.65) | ELANEEPHX2CTSGMAPTALDH1A1 | |
| SCHEMBL28907722 | 0.80 | EPHX2 (0.78) | ELANEEPHX2CTSGACLYMAPT | |
| Aurantioobtusin SCHEMBL3189231 | 0.79 | EPHX2 (0.76) | ELANEEPHX2ACLYMAPTALDH1A1 | |
| Aurantioobtusin SCHEMBL30643536 | 0.79 | EPHX2 (0.76) | ELANEEPHX2ACLYMAPTALDH1A1 | |
| SCHEMBL29871062 | 0.78 | EPHX2 (0.66) | ELANEEPHX2CTSGMAPTPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | ELANE 2550/4885EPHX2 2549/4885CTSG 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.